Regencell Bioscience Holdings Stock Performance
| RGC Stock | USD 6.32 0.33 5.51% |
On a scale of 0 to 100, Regencell Bioscience holds a performance score of 2. The company holds a Beta of -0.76, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Regencell Bioscience are expected to decrease at a much lower rate. During the bear market, Regencell Bioscience is likely to outperform the market. Please check Regencell Bioscience's jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Regencell Bioscience's historical price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Regencell Bioscience Holdings are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak technical and fundamental indicators, Regencell Bioscience exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.51 | Five Day Return 3.27 | Year To Date Return (39.81) | Ten Year Return (39.81) | All Time Return (39.81) |
1 | Former Regal Fund Managers to Launch New Healthcare Investment Fund | 09/24/2024 |
2 | On November 11, Visit Regal to Celebrate Americas Veterans with Popcorn and Movies | 11/04/2024 |
3 | Earnings call Regal Rexnord reports mixed Q3 results amid market headwinds | 11/06/2024 |
4 | Regencell Bioscience Stock Plummets Amidst Lackluster Financial Performance | 11/11/2024 |
5 | Regal Partners Ltd Trims Position in Barrick Gold Corp | 11/14/2024 |
6 | There May Be Underlying Issues With The Quality Of Regals Earnings | 11/15/2024 |
7 | Trading Report - Stock Traders Daily | 11/19/2024 |
8 | RGC Resources, Inc. Raises Annual Dividend to 0.83 per Share | 11/22/2024 |
9 | RGC Resources, Inc. Schedules Fourth Quarter 2024 Earnings Call | 11/25/2024 |
10 | Regencell Bioscience Shares Drop Amidst Market Volatility | 11/27/2024 |
| Begin Period Cash Flow | 1.6 M |
Regencell |
Regencell Bioscience Relative Risk vs. Return Landscape
If you would invest 655.00 in Regencell Bioscience Holdings on September 3, 2024 and sell it today you would lose (23.00) from holding Regencell Bioscience Holdings or give up 3.51% of portfolio value over 90 days. Regencell Bioscience Holdings is generating 0.3386% of daily returns assuming volatility of 9.3682% on return distribution over 90 days investment horizon. In other words, 83% of stocks are less volatile than Regencell, and above 94% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Regencell Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regencell Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Regencell Bioscience Holdings, and traders can use it to determine the average amount a Regencell Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0361
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RGC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.37 actual daily | 83 83% of assets are less volatile |
Expected Return
| 0.34 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Regencell Bioscience is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regencell Bioscience by adding it to a well-diversified portfolio.
Regencell Bioscience Fundamentals Growth
Regencell Stock prices reflect investors' perceptions of the future prospects and financial health of Regencell Bioscience, and Regencell Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regencell Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 74.37 M | ||||
| Shares Outstanding | 13.01 M | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 10.01 X | ||||
| EBITDA | (3.62 M) | ||||
| Net Income | (4.36 M) | ||||
| Cash And Equivalents | 59.41 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 85.74 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 13.94 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (4 M) | ||||
| Earnings Per Share | (0.33) X | ||||
| Market Capitalization | 82.24 M | ||||
| Total Asset | 8.44 M | ||||
| Retained Earnings | (21.62 M) | ||||
| Working Capital | 7.92 M | ||||
| Current Asset | 438.2 M | ||||
| Current Liabilities | 551.3 M | ||||
About Regencell Bioscience Performance
By analyzing Regencell Bioscience's fundamental ratios, stakeholders can gain valuable insights into Regencell Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Regencell Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Regencell Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 67.96 | 71.35 | |
| Return On Tangible Assets | (0.51) | 0.05 | |
| Return On Capital Employed | (0.57) | 0.12 | |
| Return On Assets | (0.51) | 0.04 | |
| Return On Equity | (0.52) | (0.13) |
Things to note about Regencell Bioscience performance evaluation
Checking the ongoing alerts about Regencell Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Regencell Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regencell Bioscience had very high historical volatility over the last 90 days | |
| Reported Net Loss for the year was (4.36 M) with profit before taxes, overhead, and interest of 0. | |
| Regencell Bioscience Holdings has about 59.41 K in cash with (4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 89.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Regencell Bioscience Shares Drop Amidst Market Volatility |
- Analyzing Regencell Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regencell Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Regencell Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regencell Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regencell Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regencell Bioscience's stock. These opinions can provide insight into Regencell Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |